An interventional study of Magnesium Sulfate (2 Ampoules) and Dexketoprofen in Dysmenorrhea, sponsored by Havva Betül Bacak. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-11-25.
Sponsored by Havva Betül Bacak · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Dysmenorrhea with a site in Turkey — 19 open to participants now, 23 under way, none of them phase 3. Dysmenorrhea · Turkey.
Among the 81 studies in Dysmenorrhea with a site in Turkey, this one is the 36th largest by planned enrollment of the 72 interventional ones that give a count, is one of 13 that started in 2025, is one of 70 with no phase, reaches primary completion later than 13 of the 22 other live ones, and was the 64th registered.
432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.
Browse Dysmenorrhea studies →19 of the 81 studies in Dysmenorrhea with a site in Turkey are open now. Recruiting first, the newest first:
Tokat Gaziosmanpasa University · Sites in Turkey
Ages 18+ · Women only · Healthy volunteers
Istanbul Medipol University Hospital · Sites in Turkey
Ages 18–30 · Women only
Ankara University · Sites in Turkey
Ages 18–25 · Women only
Nigde Omer Halisdemir University · Sites in Turkey
Ages 18–30 · Women only · Healthy volunteers
Acibadem University · Sites in Turkey
Ages 10–19 · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 11 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 35 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 62 across 364 interventional studies indexed under Dysmenorrhea.
Median enrollment 60 across the 72 interventional studies, 60 across the 9 observational. Of the 52 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 81 has an industry lead sponsor. The 10 most frequent:
Havva Betül Bacak is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Havva Betül Bacak has 1 study filed under Dysmenorrhea — fewer than ten, so there is no comparison to draw.
2 of the studies in Dysmenorrhea with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06398990Acibadem UniversityThe Effect of Cognitive Exercise Therapy Approach and Yoga in Adolescents With Dysmenorrhoea | 2026-12 |
| NCT07409337Nigde Omer Halisdemir UniversitySelf-Acupressure for Primary Dysmenorrhea and Premenstrual Symptoms | 2026-12-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 81 studies in Dysmenorrhea with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, randomized, double-blind clinical trial aims to evaluate the analgesic efficacy of intravenous magnesium sulfate in women presenting to the emergency department with acute dysmenorrhea. Participants will be randomized into two groups receiving either 2 ampoules of magnesium sulfate or intravenous dexketoprofen. Pain levels will be assessed using the Visual Analog Scale (VAS) before and after treatment.
This prospective, randomized, double-blind clinical trial is designed to evaluate the analgesic effectiveness of intravenous magnesium sulfate in women aged 18 to 35 years presenting to the emergency department with acute dysmenorrhea. Participants will be randomly assigned to one of two treatment groups: 2 ampoules of magnesium sulfate or intravenous dexketoprofen.
All medications will be diluted in 100 ml of normal saline and administered intravenously over 15 minutes. Pain intensity will be assessed using the Visual Analog Scale (VAS) before treatment and 1 hour after administration. Secondary outcomes include patient satisfaction, vital sign changes, and adverse effects.
The study aims to compare the analgesic efficacy and safety profile of intravenous magnesium sulfate with that of a standard nonsteroidal anti-inflammatory drug (dexketoprofen) in the management of acute dysmenorrhea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female patients aged 18 to 35 years
Presenting to the obstetrics and gynecology emergency department with a diagnosis of primary dysmenorrhea
Having regular menstrual cycles within the last 6 months
Having a Visual Analog Scale (VAS) pain score of ≥6 at emergency admission
Providing written for participation in the study
Exclusion Criteria:
Patients with secondary dysmenorrhea or underlying gynecological pathology
Pregnancy or breastfeeding
Use of analgesics or muscle relaxants within the last 3 days
Known allergy to magnesium sulfate or dexketoprofen trometamol
History of renal failure, cardiac arrhythmia, or serious systemic disease
Inability to assess pain due to mental disability or communication disorder
Failure to provide for participation in the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 2 ampoules (8 ml total) of intravenous magnesium sulfate diluted in 100 ml normal saline, administered over 15 minutes.
Drug: Magnesium Sulfate (2 Ampoules)
Participants receive 50 mg of intravenous dexketoprofen diluted in 100 ml normal saline, administered over 15 minutes.
Drug: Dexketoprofen
Intravenous administration of 2 ampoules (8 ml total) of magnesium sulfate diluted in 100 ml normal saline, infused over 15 minutes.
Intravenous administration of 50 mg dexketoprofen diluted in 100 ml normal saline, infused over 15 minutes.
Change in pain intensity measured by Visual Analog Scale (VAS)
Pain severity will be assessed using the 0-10 Visual Analog Scale (VAS) before treatment and 1 hour post-treatment. The study will evaluate and compare the analgesic effect of two different doses of intravenous magnesium sulfate (2 ampoules vs. 3 ampoules) and compare both to intravenous dexketoprofen in women presenting with acute dysmenorrhea.
Time frame: Baseline and 1 hour after intravenous treatment
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jan 2026, 6 months after the start.
Of 178 non-industry interventional studies with no phase under Dysmenorrhea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 6 months is below that.
Counting every sponsor, half of 188 studies reached it within 8 months; a quarter within 3 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Magnesium Sulfate
Havva Betül Bacak